What is Takeda Pharmaceutical Co - ADR Annual Revenue?

Takeda Pharmaceutical Co - ADR Annual Revenue rose 5.87%, in the last year to $4,263,762 M. Its sector's average revenue growth for the last fiscal year was 7.47%.

What is Takeda Pharmaceutical Co - ADR Annual Net Profit?

Takeda Pharmaceutical Co - ADR Annual Net Profit fell 54.56% in the last year to $144,067 M. Its sector's average net profit growth for the last fiscal year was -32.47%.

What is Takeda Pharmaceutical Co - ADR Price to Earning Ratio?

Takeda Pharmaceutical Co - ADR Price to Earning Ratio is 34.24, higher than its sector PE ratio of 4.3.

What is Takeda Pharmaceutical Co - ADR Stock Price?

Takeda Pharmaceutical Co - ADR Stock Price rose 4.91% and underperformed its sector by 4.45% in the past year.

What is Takeda Pharmaceutical Co - ADR Quarterly Revenue?

Takeda Pharmaceutical Co - ADR Quarterly Revenue rose 2.96% YoY to $1,144,124 M. Its sector's average revenue growth YoY for the quarter was 5.97%.

What is Takeda Pharmaceutical Co - ADR Quarterly Net profit?

Takeda Pharmaceutical Co - ADR Quarterly Net profit fell 77.5% YoY to $23,789 M. Its sector's average net profit growth YoY for the quarter was -47.43%.

What is Takeda Pharmaceutical Co - ADR Debt to Equity Ratio?

Takeda Pharmaceutical Co - ADR Debt to Equity Ratio of 0.67 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Takeda Pharmaceutical Co - ADR Return on Equity(ROE)?

Takeda Pharmaceutical Co - ADR Return on Equity(ROE) for the last financial year was 2.11%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Takeda Pharmaceutical Co - ADR Mutual Fund Holding?

Takeda Pharmaceutical Co - ADR Mutual Fund Holding decreased by 0.04% in the last quarter to 1.15.

What is Takeda Pharmaceutical Co - ADR Interest Coverage Ratio?

Takeda Pharmaceutical Co - ADR Interest Coverage Ratio is 1.44, in the normal range of 1 to 1.5.

What is Takeda Pharmaceutical Co - ADR Institutional Holding?

Takeda Pharmaceutical Co - ADR Institutional Holding decreased by 0.1% in the last quarter to 2.32.

How is the Takeda Pharmaceutical Co - ADR today?

The Takeda Pharmaceutical Co - ADR today is trading in the green, up by 1.13% at 15.18.

How has Takeda Pharmaceutical Co - ADR performed historically?

The Takeda Pharmaceutical Co - ADR is currently trading up 1.13% on an intraday basis in the past week the index rose 0.93%. The index has been up 13.62% in the past quarter and rose 4.91% in the past year. You can view this in the overview section.

Takeda Pharmaceutical Co - ADR XNYS: TAK

Takeda Pharmaceutical Co - ADR Live Share Price Today, Share Analysis and Chart

Name: Takeda Pharmaceutical Co - ADR: Is Infosys Ltd. worth buying?
Item: Takeda Pharmaceutical Co - ADR
Rating: 2.944750125
Author: Trendlyne DVM scores

Mid-range Performer

Download real time

15.18 0.17 (1.13%)

New 52W High today

1.3M XNYS Volume

XNYS 17 Mar, 2025 5:30 PM (EDT)

Takeda Pharmaceutical Co -... Key Metrics

My Metrics

Select

Market Capitalization High in industry Unavailable in chosen country	47,962.7
PE TTM High in industry Unavailable in chosen country	34.2
PEG TTM High in industry Unavailable in chosen country	2
Price to Book High in industry Unavailable in chosen country	144.1
Institutional holding current Qtr % Low in industry Unavailable in chosen country	2.3
Revenue Growth Qtr YoY % Below industry Median Unavailable in chosen country	3
Operating Revenue growth TTM % Below industry Median Unavailable in chosen country	9.8
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-77.5
Net Profit TTM Growth % Below industry Median Unavailable in chosen country	16.7
Operating Profit Margin Qtr % Negative Operating Profit Margin Qtr % Unavailable in chosen country	-2
Operating Profit Margin TTM % Below industry Median Unavailable in chosen country	11.2
Piotroski Score High in industry Unavailable in chosen country	7
Rel Perf vs Sector quarter% Unavailable in chosen country	7.2
ROE Annual % High in industry Unavailable in chosen country	2.1
RoA Annual % High in industry Unavailable in chosen country	1

All financials are in JPY Million and price data in USD

High Financial Strength

66.7 / 100

Mid Valuation

44.2 / 100

Technically Neutral

58.1 / 100

Mid-range Performer These stocks are with strong quality. Their reasonable financials and technical aspects successfully gather investor's interest. View Similar Embed DVM

1Yr Price target upside is 10%

4 analysts

Check Before You Buy

Check P/E Buy Sell Zone

Strong Sell Zone

100.0 % into P/E buy sell zone

Strong upside potential

% time spent below current P/E

Gains already realized

Takeda Pharmaceutical Co -... Stock Price Analysis

Day Price Range 1.1% 1 Day return Unavailable in chosen country	15.2 (LTP) 1515.2 LowHigh
Week Price Range 0.9% 1 Week return Unavailable in chosen country	15.2 (LTP) 14.815.2 LowHigh
Month Price Range 12.1% 1 Month return Unavailable in chosen country	15.2 (LTP) 13.715.2 LowHigh
52 Week Price Range 4.9% 1 Year return Unavailable in chosen country	15.2 (LTP) 12.615.2 LowHigh

View full Share Price History

Takeda Pharmaceutical Co -... Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Hit

Takeda Pharmaceutical Co - ADR's Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

0.3

Avg. Estimate

0.3

Low Estimate

0.3

High Estimate

0.3

Current EPS

Avg. Estimate

Miss

EPS is expected to reduce by 6.7% in FY25

Consensus Recommendation

4 ANALYST Recommendations

BUY

The consensus recommendation from 4 analysts for Takeda Pharmaceutical Co - ADR is BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Takeda Pharmaceutical Co -... Stock Analysis

Takeda Pharmaceutical Co -... stock analysis with key metrics, changes, and trends.

Takeda Pharmaceutical Co -... Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$4,263,762 M	5.87%	positive	Annual Revenue rose 5.87%, in the last year to $4,263,762 M. Its sector's average revenue growth for the last fiscal year was 7.47%.
Annual Net Profit	$144,067 M	54.56%	negative	Annual Net Profit fell 54.56% in the last year to $144,067 M. Its sector's average net profit growth for the last fiscal year was -32.47%.
Price to Earning Ratio	34.24	-	negative	Price to Earning Ratio is 34.24, higher than its sector PE ratio of 4.3.
Stock Price	$15.18	4.91%	negative	Stock Price rose 4.91% and underperformed its sector by 4.45% in the past year.
Quarterly Revenue	$1,144,124 M	2.96%	positive	Quarterly Revenue rose 2.96% YoY to $1,144,124 M. Its sector's average revenue growth YoY for the quarter was 5.97%.
Quarterly Net profit	$23,789 M	77.5%	negative	Quarterly Net profit fell 77.5% YoY to $23,789 M. Its sector's average net profit growth YoY for the quarter was -47.43%.
Debt to Equity Ratio	0.67	-	positive	Debt to Equity Ratio of 0.67 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	2.11 %	2.11%	negative	Return on Equity(ROE) for the last financial year was 2.11%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	1.15 %	-0.04%	negative	Mutual Fund Holding decreased by 0.04% in the last quarter to 1.15.
Interest Coverage Ratio	1.44	-	neutral	Interest Coverage Ratio is 1.44, in the normal range of 1 to 1.5.
Institutional Holding	2.32 %	-0.1%	negative	Institutional Holding decreased by 0.1% in the last quarter to 2.32.

VIEW LESS

Loading data..

Takeda Pharmaceutical Co - ADR - Company Profile

What does Takeda Pharmaceutical Co - ADR do?

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Year

Ms. Asuka Miyabashira

President, Japan Pharma Business Unit

2024

43 M

2024

Gross Remuneration

Year

Takeda Pharmaceutical Co - ADR Live Share Price Today, Share Analysis and Chart

New 52W High today

Takeda Pharmaceutical Co -... Key Metrics

Market Capitalization

PE TTM

PEG TTM

Rel Perf vs Sector quarter%

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

ROE Annual %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

RoA Annual %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

Check Before You Buy

Check P/E Buy Sell Zone

Takeda Pharmaceutical Co -... Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Takeda Pharmaceutical Co -... Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Takeda Pharmaceutical Co - ADR's Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

EPS is expected to reduce by 6.7% in FY25

Consensus Recommendation

The consensus recommendation from 4 analysts for Takeda Pharmaceutical Co - ADR is BUY

Takeda Pharmaceutical Co -... Stock Analysis

Takeda Pharmaceutical Co -... stock analysis with key metrics, changes, and trends.

Annual Revenue rose 5.87%, in the last year to $4,263,762 M. Its sector's average revenue growth for the last fiscal year was 7.47%.

Annual Net Profit fell 54.56% in the last year to $144,067 M. Its sector's average net profit growth for the last fiscal year was -32.47%.

Price to Earning Ratio is 34.24, higher than its sector PE ratio of 4.3.

Stock Price rose 4.91% and underperformed its sector by 4.45% in the past year.

Quarterly Revenue rose 2.96% YoY to $1,144,124 M. Its sector's average revenue growth YoY for the quarter was 5.97%.

Quarterly Net profit fell 77.5% YoY to $23,789 M. Its sector's average net profit growth YoY for the quarter was -47.43%.

Debt to Equity Ratio of 0.67 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was 2.11%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding decreased by 0.04% in the last quarter to 1.15.

Interest Coverage Ratio is 1.44, in the normal range of 1 to 1.5.

Institutional Holding decreased by 0.1% in the last quarter to 2.32.

Takeda Pharmaceutical Co - ADR - Company Profile

What does Takeda Pharmaceutical Co - ADR do?

Takeda Pharmaceutical Co - ADR Management structure

Mr. Christophe Weber

Director, President and Chief Executive Officer; Head of Global Business of Takeda Pharmaceuticals U. S. A. , Inc.

Mr. Costa Saroukos

Director and Chief Financial Officer

Mr. Masato Iwasaki,, PhD

Director and Director, Japan General Affairs

Mr. Andrew S. Plump, M.D.

Director and President, Research and Development

Ms. Elaine Shannon

Global Quality Officer

Ms. Asuka Miyabashira

President, Japan Pharma Business Unit

Takeda Pharmaceutical Co - ADR Board of directors

Ms. Emiko Higashi

Independent Director

Mr. Michel Orsinger